ArticleInternational journal of molecular sciences2021

Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.

Inken Salewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.